PUBLICATIONS
-
Hather, G.J., Haynes, W., Higdon, R., Kolker, N., Stewart, E.A., et al. (2010) The United States of America and Scientific Research. PLoS ONE 5(8): e12203. doi:10.1371/journal.pone.0012203.
Ozdemir, V. (2010) “ELSI research in an era of synthetic biology and the Human Microbiome Project: Recognizing context sensitivity.” AAPS Pharmacogenomics Focus Group PGx Highlights (September issue)
Ozdemir, V., Knoppers, B.M. (2010) “One size does not fit all: Toward “upstream ethics”? American Journal of Bioethics 10(6): 42-44.
Ozdemir, V. (2010) “Pharmacogenomics: Reflecting on the old and new social, ethical and policy issues in postgenomics medicine.” In:Pharmacogenetics in Psychiatry. A Volume in the Series for Advances in Biological Psychiatry. Editors: M. Schwab (Stuttgart), W. Kaschka (Ulm), E. Spina (Messina). S. Karger AB: Basel, Switzerland. pp. 12-29.
Suzuki, Y., Sugai, T., Fukui, N., Watanabe, J., Ono, S., Inoue, Y., Ozdemir, V., Someya, T. (2010) “CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.” Journal of Psychopharmacology.
Ozdemir, V., Husereau, D., Hyland, S., Samper, S., Salleh, M.Z. (2009) “Personalized medicine beyond genomics: New technologies, global health diplomacy and anticipatory governance“. Current Pharmacogenomics and Personalized Medicine 7(4): 225-230.
Paik, Y.K., Graham, J.E., Jones, M., McDonald, F., Holmes, C., Ozdemir, V. (2009) “Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): Pharmacoproteomics and the approaching wave of “proteomics diagnostics”. Current Pharmacogenomics and Personalized Medicine 7(4): 243-248.
Ozdemir, V. (2009) “What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks”. American Journal of Bioethics 9(11): 65-68.
Ozdemir, V., Someya, T. (2009). “A transdisciplinary forum for study of individual and population variability in response to health interventions and personalized medicine.” Current Pharmacogenomics and Personalized Medicine 7(3): 146-148.
Ozdemir, V., Suarez-Kurtz, G., Stenne, R., Somogyi, A., Someya, T., Kayaalp, S.O., Kolker, E. (2009) “Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of “edge effect” and cultivating an ethical bridge between omics innovations and society“. OMICS: A Journal of Integrative Biology 13(1): 43-62.
Ozdemir, V., Motulsky, A.G., Kolker, E., Godard, B. (2009) “Genome-environment interactions and prospective technology assessment: Evolution from pharmacogenomics to nutrigenomics and ecogenomics”. OMICS: A Journal of Integrative Biology 13(1): 1-6.
Godard, B., Ozdemir, V., Fortin, M., Egalité, N. (2009) “Ethnocultural community leaders’ perceptions on population specific genomics research and large scale biobanks: A qualitative research study”. Public Understanding of Science, June 12th Epub ahead of print.
Suzuki, Y., Watanabe, J., Fukui, N., Ozdemir, V., Someya, T. (2009) “Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.” British Medical Journal 2009; 338: a1792.
Aklillu, E., Karlsson, S., Zachrisson, O., Ozdemir, V., Ågren, H. (2009) “Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression”. Pharmacogenetics and Genomics 19(4): 267-75.
Ozdemir, V., Graham, J.E., Godard, B. (2008) “Race as a variable in pharmacogenomics science: From empirical ethics to publication standards”. Pharmacogenetics and Genomics 18(10): 837-41.
Master, Z., Ozdemir, V. (2008) “Selling translational research: Is science a value neutral autonomous enterprise?” American Journal of Bioethics 8(3): 52-4.
Ozdemir, V., Godard, B. (2007) “Evidence Based Management of Nutrigenomics Expectations and ELSIs”. Pharmacogenomics 8(8): 1051-62.
Ozdemir, V., Williams-Jones, B., Cooper, D.M., Someya, T., Godard, B. (2007) “Mapping Translational Research in Personalized Therapeutics: From Molecular Markers to Health Policy”. Pharmacogenomics 8(2): 177-85.
Ozdemir, V., Godard, B. (2007) “Crossing the blood-brain-barrier: Integration of scientific innovation with socio-ethical reflection”. Psychiatric Times 24(10): 1-3.
Aklillu, E., Kalow, W., Endrenyi, L., Miura, J., Harper, P., Ozdemir, V. (2007) “Differential contributions of CYP2D6 and DRD2 to pharmacodynamic sensitivity and time course of prolactin response to perphenazine” Pharmacogenetics and Genomics 17: 889-93.
Li, Q., Chen, B.L., Ozdemir, V., Ji, W., Mao, Y.M., Wang, L.C., Lei, H.P., Fan, L., Zhang, W., Liu, J., Zhou, H.H. (2007) “Frequency of genetic polymorphisms of COX1, P2Y1, GPIIIa in a Chinese population and association with attenuated response to aspirin” Pharmacogenomics 8: 577-86.
Ozdemir, V., Bertilsson, L., Miura, J., Carpenter, E., Reist, C., Harper, P., Widén, J., Svensson, J.O., Albers, L.J., Kennedy, J.L., Endrenyi, L., Kalow, W. (2007) “CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk re-visited”. Pharmacogenetics and Genomics 17: 339-47.
Someya, T., Sawamura, K., Fukui, N., Ozdemir, V. (2007) “The present state and the issue of pharmacogenetics/pharmacogenomics in clinical psychiatry” Japanese Journal of Clinical Psychopharmacology 10: 1403-07.
Zhang, W., Chen, B.L., Ozdemir, V., He, Y.J., Zhou, G., Peng, D.D., Fan, L., Yu, B.N., Xie, Q.Y., Xie, W., Wang, L.C., Wang, A., Zhou, H.H. (2007) “SLCO1B1 521T>C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients” British Journal of Clinical Pharmacology 64: 346-52.
Ozdemir, V., Günes, A., Dahl, M.-L., Scordo, M.G., Williams-Jones, B., Someya, T. (2006) “Could Endogenous Substrates of Drug-Metabolizing Enzymes Influence Constitutive Physiology and Drug Target Responsiveness?” Pharmacogenomics 7(8): 1199-210.
Ozdemir, V., Williams-Jones, B., Glatt, S.J., Tsuang, M.T., Lohr, J.B., Reist, C. (2006) “Shifting emphasis from pharmacogenomics to theragnostics” Nature Biotechnology 24(8): 942-46.
Ozdemir, V., Aklillu, E., Mee, S., Bertilsson, L., Albers, L.J., Graham, J.E., Caligiuri, M., Lohr, J.B., Reist, C. (2006) “Pharmacogenetics for off-patent antipsychotics: re-framing the risk for tardive dyskinesia and access to essential medicines” Expert Opinion on Pharmacotherapy 7: 119-33.
Ozdemir, V., Kalow, W., Tothfalusi, L., Bertilsson, L., Endrenyi, L., Graham, J.E. (2005) “Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions” Current Pharmacogenomics and Personalized Medicine 3: 53-71.
Kalow, W., Ozdemir, V., Tothfalusi, L. (2001) “Multigenic traits and risk assessment in pharmacology: a population approach” Pharmacogenomics Journal 1: 234-36.
Ozdemir, V., Kalow, W., Tang, B.K., Paterson, A.D., Walker, S.E., Endrenyi, L., Kashuba, A.D.M. (2000) “Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method” Pharmacogenetics and Genomics 10: 373-88.
Kalow, W., Ozdemir, V., Tang, B.K., Tothfalusi, L., Endrenyi, L. (1999) “The science of pharmacological variability: An essay” Clinical Pharmacology & Therapeutics 66: 445-47.
Ozdemir, V., Naranjo, C.A., Herrmann, N., Reed, K., Sellers, E.M., Kalow, W. (1997) Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clinical Pharmacology & Therapeutics 62(3): 334-47.